博安生物(06955)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06955 博安生物

休市中 06-12 16:08:21

5.000

+0.190

+3.95%

最高5.180	最低4.880	成交量617.30万
今开4.960	昨收4.810	日振幅6.24%
总市值31.10亿	流通市值31.12亿	总股本6.22亿
成交额3,084万	换手率0.99%	流通股本6.22亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06955","market":"HK","secType":"STK","nameCN":"博安生物","latestPrice":5,"timestamp":1781251701010,"preClose":4.81,"halted":0,"volume":6173000,"delay":0,"changeRate":0.039501039501039586,"floatShares":622333694,"shares":622000000,"eps":0.15821361016338203,"marketStatus":"休市中","change":0.19,"latestTime":"06-12 16:08:21","open":4.96,"high":5.18,"low":4.88,"amount":30844532,"amplitude":0.06237,"askPrice":5,"askSize":28000,"bidPrice":4.91,"bidSize":40000,"shortable":3,"etf":0,"ttmEps":0.06527905859029111,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781487000000},"marketStatusCode":7,"adr":0,"listingDate":1672329600000,"exchange":"SEHK","adjPreClose":4.81,"openAndCloseTimeList":[[1781227800000,1781236800000],[1781240400000,1781251200000]],"volumeRatio":1.229377603928676,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06955","defaultTab":"news","newsList":[{"id":"2642428098","title":"博安生物(06955)：度拉糖肽注射液完成在美国授权","url":"https://stock-news.laohu8.com/highlight/detail?id=2642428098","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642428098?lang=zh_cn&edition=full","pubTime":"2026-06-11 22:03","pubTimestamp":1781186601,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博安生物 发布公告，本公司已与合作伙伴就度拉糖肽注射液BA5101的美国市场权益达成授权协议。在美国，Trulicity获批作为饮食和运动的辅助手段，用于改善成人及≥10 岁儿童2型糖尿病患者的血糖控制，以及用于降低已确诊心血管疾病或具有多种心血管风险因素的2型糖尿病成人患者发生主要不良心血管事件的风险。BA5101有望提升度拉糖肽的用药可及性，为全球广大2型糖尿病患者提供高品质、可负担的治疗新选择。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453407.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"博安生物(06955)：度拉糖肽注射液完成在美国授权","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06955","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184605032","title":"博安生物5月无新增发行或股份变动，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1184605032","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184605032?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:47","pubTimestamp":1780476422,"startTime":"0","endTime":"0","summary":"2026年6月3日，山东博安生物技术股份有限公司发布截至2026年5月31日的证券变动月报表。报告显示，公司本月未进行新的股份发行、购回或注销，股本结构未发生变化。截至本月末，公司已发行股份合计622,333,694股，库存股份数目为0股。当月间并无股份期权、权证或可换股票据等权益工具的授出、行使或失效记录。报告称，公司已遵守香港联合交易所有限公司的相关上市规则及其他适用法律规定。本期月报由公司董事姜华签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639624214","title":"博安生物(06955)：两款地舒单抗注射液在美国提交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2639624214","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639624214?lang=zh_cn&edition=full","pubTime":"2026-05-29 19:33","pubTimestamp":1780054380,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博安生物 发布公告，本公司已向美国食品药品监督管理局提交BA6101和BA1102 的生物制品许可申请。BA6101和BA1102分别为地舒单抗注射液原研药Prolia和Xgeva的生物类似药，此次在美国申请的适应症涵盖原研药的全部适应症，即BA6101用于骨质疏松症相关治疗，BA1102用于实体瘤骨转移和多发性骨髓瘤、骨巨细胞瘤、高钙血症的相关治疗。两款产品已在中国上市并在临床应用中获得医生与患者的积极反馈。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447942.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","06955","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109690044","title":"博安生物(06955.HK)拟回购最多10%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1109690044","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109690044?lang=zh_cn&edition=full","pubTime":"2026-05-27 21:56","pubTimestamp":1779890182,"startTime":"0","endTime":"0","summary":"博安生物于5月27日公告，公司董事会建议在即将召开的股东周年大会上寻求授权，回购不超过已发行股份总数10%的股份。根据公告，截至最近可行日期，公司已发行约6.22亿股H股，若董事会获授权，回购上限约为6223万股。该事项将提交股东于2026年6月22日（星期一）上午10时召开的股东周年大会审议表决。董事会认为，股份购回有助于维护公司与股东利益，并帮助优化公司资本结构。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"博安生物(06955.HK)拟回购最多10%股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126539730","title":"博安生物宣布\"博罗加\"（地舒单抗注射液）获国家药监局批准用于骨转移治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1126539730","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126539730?lang=zh_cn&edition=full","pubTime":"2026-05-26 17:01","pubTimestamp":1779786118,"startTime":"0","endTime":"0","summary":"5月26日，山东博安生物技术股份有限公司（06955.HK）宣布，其产品\"博罗加\"（地舒单抗注射液）已获得中国国家药品监督管理局的批准，用于治疗骨转移。\n此次获批标志着该药物在中国市场取得了重要进展，为相关患者提供了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638552560","title":"博安生物(06955)：地舒单抗注射液博洛加®新适应症在中国获批 用于治疗实体肿瘤骨转移和多发性骨髓瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2638552560","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638552560?lang=zh_cn&edition=full","pubTime":"2026-05-26 12:18","pubTimestamp":1779769098,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博安生物 发布公告，中国国家药品监督管理局已批准博洛加的新增适应症补充申请，用于实体肿瘤骨转移患者或多发性骨髓瘤患者的治疗，以延迟或降低骨相关事件的发生风险。该产品于2024年5月首次在中国获批上市，用于治疗骨巨细胞瘤。骨相关事件是骨转移常见的并发症，包括病理性骨折、脊髓压迫等，可显著降低患者生活质量并影响预后。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"博安生物(06955)：地舒单抗注射液博洛加®新适应症在中国获批 用于治疗实体肿瘤骨转移和多发性骨髓瘤","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06955","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638534935","title":"格隆汇个股放量排行榜 | 5月25日","url":"https://stock-news.laohu8.com/highlight/detail?id=2638534935","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638534935?lang=zh_cn&edition=full","pubTime":"2026-05-25 17:30","pubTimestamp":1779701404,"startTime":"0","endTime":"0","summary":"股票名称成交额（万）量比持续放量天数天利控股集团26177.222.493百富环球2703.382.425中联发展控股1067.482.361优必选217973.061.981华润医疗1719.231.911滔搏3529.591.832胜宏科技350159.461.791数码通电讯961.431.781九龙仓集团17387.851.641蔚来-SW46990.051.551高鑫零售1589.461.521科伦博泰生物60133.001.496九福来102.461.451中集集团7903.471.441北大青鸟环宇360.511.371PACIFIC LEGEND740.851.361中海油田服务9347.601.361MOS HOUSE695.301.331百果园集团641.011.291中芯国际1651388.781.282量化派3423.981.231佰泽医疗5107.781.191时代天使8886.501.192五一视界215348.591.182稀美资源-五百6200.381.1710电讯盈科6323.451.171美格智能7545.751.171深圳高速公路股份1185.201.172森松国际19247.321.143兖矿能源47039.851.111大象未来集团855.821.091通通AI社交2016.021.061兆易创新243","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/25173057187788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["06613","02172","02291","00107","03986","02050","09866","01473","02506","02598","09993","09869","09926","00087","09880","02142","00152","00384","00909","08547","01592","06681","02259","01919","00117","06110","03888","06699","02155","02418","00004","02609","00081","02714","06990","01211","02565","02685","00165","00177","09626","01477","01672","00981","02587","00199","01516","06955","00008","06603"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1174547353","title":"异动解读 | 博安生物盘中大涨14.97%，拟回购股份及核心产品BA5101在澳门获批","url":"https://stock-news.laohu8.com/highlight/detail?id=1174547353","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174547353?lang=zh_cn&edition=full","pubTime":"2026-05-19 10:51","pubTimestamp":1779159066,"startTime":"0","endTime":"0","summary":"博安生物今日盘中股价大幅上涨14.97%，引起市场关注。消息面上，推动股价上涨的主要因素有两个。首先，公司发布公告，计划根据股东授权，在公开市场购回价值不超过2亿港元的公司股份。其次，公司自主研发的度拉糖肽注射液正式获得中国澳门特别行政区药物监督管理局的上市批准，用于治疗成人2型糖尿病。此外，BA5101也已在美国获准开展临床试验，为其未来进入更广泛的国际市场奠定了基础。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636862698","title":"港股异动 | 博安生物(06955)盘中拉升15% 拟购回价值不超过2亿港元公司股份 BA5101于中国澳门获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2636862698","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636862698?lang=zh_cn&edition=full","pubTime":"2026-05-19 10:35","pubTimestamp":1779158139,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，博安生物盘中拉升逾15%，截至发稿，涨7.64%，报6.77港元，成交额1.56亿港元。另外，据博安生物官微消息，其自主开发的度拉糖肽注射液正式获得中国澳门特别行政区政府药物监督管理局的上市批准，用于成人2型糖尿病患者的血糖控制。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443279.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","06955","BK4585","BK1161","BK4588","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635139738","title":"博安生物：拟回购不超过2.00亿港元股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2635139738","media":"南方财经网","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635139738?lang=zh_cn&edition=full","pubTime":"2026-05-13 21:57","pubTimestamp":1778680620,"startTime":"0","endTime":"0","summary":"南财智讯5月13日电，博安生物（06955.HK）发布自愿公告，公司董事会宣布拟根据股东于2025年6月5日周年大会批准的购回授权，在公开市场上回购价值不超过20000.00万港元（即2.00亿港元）的本公司股份。本次回购将严格遵守香港联合交易所《证券上市规则》第10.06条等相关规定，不得在敏感期（如业绩公告前30日内）进行。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605133736257148.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06955","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182163093","title":"博安生物4月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1182163093","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182163093?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:37","pubTimestamp":1778143050,"startTime":"0","endTime":"0","summary":"山东博安生物技术股份有限公司于2026年5月7日发布2026年4月股份变动月报表，报告期为2026年4月1日至4月30日。公告显示，博安生物注册股本为人民币622,333,694元，普通股类别为H股，面值每股人民币1元。报告期内未出现新增发行、购回、注销或库藏股变动，公司股本维持稳定。截至4月30日，博安生物仍符合相关上市规则关于公众持股量的规定。本次公告由董事姜华签署。公司确认本月的所有股份变动安排均已合法合规办理。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632612888","title":"股价8个月最多跌去近7成，博安生物(06955)何以“保通”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2632612888","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632612888?lang=zh_cn&edition=full","pubTime":"2026-05-01 20:28","pubTimestamp":1777638537,"startTime":"0","endTime":"0","summary":"今年3月31日，即披露2025年年报业绩的次日，博安生物盘中股价最低触及6.12港元，刷新公司上市以来的股价新低。然而随着公司股价的一路下跌，截至4月30日，博安生物检讨期内日均市值已跌至62.35亿港元，已低于67.50亿港元的保通门槛，正处于“出通边缘”。从技术面来看，去年8月以来，博安生物一直处于“价跌量缩”的下行通道中。目前来看，市场更看重的无疑是博安生物创新管线的进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437626.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147689866","title":"博安生物2025年营收7.85亿元扭亏为盈，研发与国际化布局稳步推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1147689866","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147689866?lang=zh_cn&edition=full","pubTime":"2026-04-29 22:11","pubTimestamp":1777471903,"startTime":"0","endTime":"0","summary":"2025年度，博安生物实现收入7.85亿元人民币，同比上升约8.1%。公司全年毛利总额为5.62亿元，毛利率约71.6%，较上年度的74.7%略有回落。同期研发投入保持高水平，全年研发开支为1.48亿元左右，略低于上一年度。销售及经销开支则同比增加近两成，主要用于完善商业化团队和持续市场推广。净利润方面，公司由2024年度约-0.73亿元的亏损转为2025年度约0.07亿元的净溢利，实现扭亏为盈。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"博安生物2025年营收7.85亿元扭亏为盈，研发与国际化布局稳步推进","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630300751","title":"博安生物(06955)建议采纳限制性股票单位激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2630300751","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630300751?lang=zh_cn&edition=full","pubTime":"2026-04-28 21:35","pubTimestamp":1777383310,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博安生物(06955)发布公告，于2026年4月28日，董事会议决建议就本公司H股采纳限制性股票单位激励计划(限制性股票单位激励计划)。限制性股票单位激励计划旨在进一步完善本公司的长效人才激励架构，激励核心雇员为本公司的发展作出贡献，促进本公司股东、本公司及管理团队间的利益更趋一致，从而助力本公司持续及稳定长期的发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435647.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06955","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630382921","title":"博安生物(06955)：BA1106联合BA1104治疗非小细胞肺癌的Ⅱ期临床试验申请获CDE受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2630382921","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630382921?lang=zh_cn&edition=full","pubTime":"2026-04-26 18:41","pubTimestamp":1777200104,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博安生物 发布公告，本公司自主开发的创新抗体BA1106联合其自有的PD-1抑制剂BA1104用于非小细胞肺癌一线和二线治疗的Ⅱ期临床试验申请，已于近日获得国家药品监督管理局药品审评中心受理。在Ⅰ期临床试验中，BA1106联合BA1104已在肺腺癌、肺鳞癌、胃癌等多种实体瘤受试者中观察到积极的疗效信号，上述受试者既往均接受过免疫检查点抑制剂治疗并出现疾病进展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434053.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06955","LU1223082196.USD","LU1223083913.SGD","CDE","BK1161","LU1223082519.USD","BK4017"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116557860","title":"博安生物3月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1116557860","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116557860?lang=zh_cn&edition=full","pubTime":"2026-04-08 21:36","pubTimestamp":1775655397,"startTime":"0","endTime":"0","summary":"2026年4月8日，山東博安生物技術股份有限公司（股票代码：06955）披露2026年3月股份变动月报表。公告显示，公司在本月无新增发行、购回或注销活动，注册股本与已发行股份数均保持622,333,694股（H股），库存股份数为0。\n报告期内，公司普通股（H股）已发行股份总数自上月底至3月末保持不变。公告确认，公司当前公众持股比例约为18.14%，继续符合香港联交所的最低公眾持股量要求。\n本次月报由公司董事姜华签署，公司声明已遵守香港联交所《上市规则》及相关法律规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624833564","title":"创新药概念股强势走高 乐普生物-B(02157)涨14.79% 机构指板块迎来多重共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2624833564","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624833564?lang=zh_cn&edition=full","pubTime":"2026-04-01 13:19","pubTimestamp":1775020740,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念股强势走高，乐普生物-B 涨14.79%，荣昌生物涨14.41%，欧康维视生物-B涨14.25%，亚盛医药-B涨12.07%，博安生物涨11.41%，诺诚健华涨11.21%，海西新药涨11.19%，三生制药涨10.78%，康诺亚-B涨10.21%。华鑫证券表示，2026年中国创新出海趋势持续强化，同时市场对创新药配置有望回升，维持医药行业“推荐”的评级。创新药迎来重要配置机遇，看好目前处于领先位置的双抗和多抗组合。期待今年年4-6月重磅学术会议带来的中国创新药企重磅研究。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1978033","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","BK1583","06955","06855","06978","02157","HK0000165453.HKD","LU1969619763.USD","BK1587","BK1191","02162","BK1574","159992","09969","LU2328871848.SGD","01530","01477","BK1161","BK1593","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623580533","title":"博安生物(06955)：王盛翰将获委任为战略委员会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=2623580533","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623580533?lang=zh_cn&edition=full","pubTime":"2026-03-31 22:10","pubTimestamp":1774966217,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博安生物(06955)发布公告，由于执行董事窦昌林博士已达法定退休年龄，自愿辞去公司执行董事、研发总裁及首席运营官、以及战略委员会主席的职务。彼于辞任后不再在公司、其附属公司或联营公司任职，自2026年3月31日起生效。自2026年3月31日起，董事会主席兼执行董事姜华女士将继任为战略委员会主席，执行董事王盛翰先生将获委任为战略委员会成员。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423392.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623407653","title":"博安生物(06955)发布年度业绩 股东应占溢利714.4万元 同比收窄90.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623407653","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623407653?lang=zh_cn&edition=full","pubTime":"2026-03-31 01:16","pubTimestamp":1774890986,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博安生物(06955)发布截至2025年12月31日止年度全年业绩，集团收入人民币7.85亿元，同比增长8.06%;股东应占溢利714.4万元，同比收窄90.24%;每股盈利0.01元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422473.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06955","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620478641","title":"博安生物(06955.HK)拟3月30日举行董事会会议以审批年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2620478641","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620478641?lang=zh_cn&edition=full","pubTime":"2026-03-17 21:47","pubTimestamp":1773755224,"startTime":"0","endTime":"0","summary":"格隆汇3月17日丨博安生物(06955.HK)公告，将于2026年3月30日(星期一)举行董事会会议，藉以(其中包括)批准公司截至2025年12月31日止年度业绩及其发布，并考虑派发末期股息(如有)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260317/32075880.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["06955","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.boan-bio.com","stockEarnings":[{"period":"1week","weight":-0.0272},{"period":"1month","weight":-0.1749},{"period":"3month","weight":-0.2918},{"period":"6month","weight":-0.4413},{"period":"1year","weight":-0.6684},{"period":"ytd","weight":-0.4145}],"compareEarnings":[{"period":"1week","weight":-0.0098},{"period":"1month","weight":-0.0633},{"period":"3month","weight":-0.0294},{"period":"6month","weight":-0.0485},{"period":"1year","weight":0.0284},{"period":"ytd","weight":-0.0356}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"山东博安生物技术股份有限公司是一家主要从事生物制药的中国公司。该公司主要从事治疗用抗体的开发、生产和商业化，专注于肿瘤学、代谢学、自身免疫学和眼科等治疗领域。该公司主要拥有三个技术平台：全人抗体转基因小鼠及噬菌体展示技术平台、双特异T-cell Engager技术平台、抗体药物偶联（ADC）技术平台。该公司主要在中国国内市场和海外市场开展其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.161165},{"month":2,"riseRate":0.5,"avgChangeRate":-0.012143},{"month":3,"riseRate":0.25,"avgChangeRate":-0.003652},{"month":4,"riseRate":0.75,"avgChangeRate":0.065191},{"month":5,"riseRate":0.25,"avgChangeRate":-0.057252},{"month":6,"riseRate":0.25,"avgChangeRate":-0.029369},{"month":7,"riseRate":0.666667,"avgChangeRate":0.172102},{"month":8,"riseRate":0,"avgChangeRate":-0.097114},{"month":9,"riseRate":0.666667,"avgChangeRate":0.038827},{"month":10,"riseRate":0,"avgChangeRate":-0.109251},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.02386},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.011932}],"exchange":"SEHK","name":"博安生物","nameEN":"BOAN BIOTECH"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博安生物(06955)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博安生物(06955)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博安生物,06955,博安生物股票,博安生物股票老虎,博安生物股票老虎国际,博安生物行情,博安生物股票行情,博安生物股价,博安生物股市,博安生物股票价格,博安生物股票交易,博安生物股票购买,博安生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博安生物(06955)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博安生物(06955)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}